The life science company Acucort reports increased revenue in the second quarter compared with the same period the previous year. Net profit deteriorated.Revenue rose to SEK 1.2 million (0.2).Net profit amounted to SEK -8.2 million (-7.6).The cash balance amounted to SEK 10.4 million at the end of the period."During the first half of the year, Acucort has translated strategy into concrete results. With important regulatory progress, a new commercial partnership and growing international interest, we are well positioned ahead of the next major milestone - our NDA application in the US," says CEO Jonas Jönmark.He goes on to say."We have delivered on the goals we set and are now entering the next phase - taking Zeqmelit further towards the US market and continuing to build AcuCort's international presence."Acucort, SEK millionQ2 2026Q2 2025Revenue1.20.2Net profit-8.2-7.6